Abstract
With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).
Original language | English (US) |
---|---|
Article number | dkq448 |
Pages (from-to) | 235-239 |
Number of pages | 5 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 66 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2011 |
Keywords
- Anticoagulants
- Antituberculosis
- Chemotherapy
- HIV
- Pulmonary hypertension
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology